Efficacy of Fluvastatin in Patients with Hypercholesterolemia / 대한내분비학회지
Journal of Korean Society of Endocrinology
;
: 75-84, 1996.
Artículo
en Coreano
| WPRIM
| ID: wpr-765533
ABSTRACT
Background:
Fluvastatin is the first entirely synthetic 3-hydroxy-3-methylglutaryl-coenzyme A(HMG-CoA) reductase inhibitor. Clinical data indicate that this agent exhibits the proven efficacy of its class and also has some theoretical advantages in safety for long-term use because of its unique pharmacololgic property consistent with hepatoselectivity(i.e., low systemic exposure). This study is to evaluate efficacy and safety of fluvastatin in hypercholesterolemic patients in Korea.Methods:
An open clinical trial with fluvastatin was conducted in 31 subjects who continued to have high blood cholesterol levels of 6.21 mmol/L(240 mg/dl) or greater after 1 month of lipid-lowering diet plus single blind placebo period. Fluvastatin was administered for 8 weeks with the initial dose of 20 mg per day and if serum cholesterol levels did not fall below 5.20 mmol/L(200 mg/dl) after 4 weeks the dose was increased to 40 mg per day for the second 4 weeks. On each visit every 4 weeks they underwent interview and laboratory tests about side effects and tolerability.Results:
The mean % changes in plasma total cholesterol and LDL-cholesterol from baseline were
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Asunto principal:
Oxidorreductasas
/
Plasma
/
Fases del Sueño
/
Triglicéridos
/
Colesterol
/
Creatina Quinasa
/
Dieta
/
Hipercolesterolemia
/
Corea (Geográfico)
Tipo de estudio:
Ensayo Clínico Controlado
Límite:
Humanos
País/Región como asunto:
Asia
Idioma:
Coreano
Revista:
Journal of Korean Society of Endocrinology
Año:
1996
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS